Legal & General Group Plc trimmed its position in Chemed Co. (NYSE:CHE - Free Report) by 11.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 31,543 shares of the company's stock after selling 4,157 shares during the quarter. Legal & General Group Plc owned approximately 0.21% of Chemed worth $16,711,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. UMB Bank n.a. lifted its position in shares of Chemed by 300.0% in the fourth quarter. UMB Bank n.a. now owns 52 shares of the company's stock valued at $28,000 after buying an additional 39 shares during the last quarter. Atala Financial Inc acquired a new stake in Chemed during the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC boosted its position in Chemed by 64.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock worth $30,000 after purchasing an additional 22 shares during the period. Trust Co. of Vermont acquired a new position in shares of Chemed in the fourth quarter valued at $34,000. Finally, Tortoise Investment Management LLC raised its position in shares of Chemed by 77.3% in the fourth quarter. Tortoise Investment Management LLC now owns 78 shares of the company's stock valued at $41,000 after purchasing an additional 34 shares during the period. 95.85% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on CHE shares. Royal Bank of Canada boosted their price target on Chemed from $633.00 to $667.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th.
View Our Latest Stock Analysis on CHE
Chemed Stock Performance
Shares of CHE traded down $0.86 during mid-day trading on Friday, reaching $580.52. The company had a trading volume of 110,655 shares, compared to its average volume of 97,899. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 29.33, a P/E/G ratio of 2.15 and a beta of 0.49. The company's 50 day simple moving average is $585.78 and its 200 day simple moving average is $567.83. Chemed Co. has a 1-year low of $512.12 and a 1-year high of $623.61.
Chemed Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend was Monday, February 24th. Chemed's payout ratio is 10.05%.
Insider Activity
In other news, CEO Kevin J. Mcnamara sold 1,000 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $615.33, for a total value of $615,330.00. Following the completion of the sale, the chief executive officer now owns 101,679 shares of the company's stock, valued at approximately $62,566,139.07. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.32% of the company's stock.
Chemed Company Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.